Jubilant Life Sciences gets final approval for Zolmitriptan Orally Disintegrating Tablets

From USFDA

Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Zolmitriptan Orally Disintegrating Tablets, 2.5 mg and 5 mg, the generic version of Zomig-ZMT (of Astra Zeneca), which is used for acute treatment of migraine headaches in adults.

Powered by Capital Market - Live News